{"id":"NCT01359956","sponsor":"National Cancer Institute, Naples","briefTitle":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","officialTitle":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-04","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2011-05-25","resultsPosted":"2020-11-13","lastUpdate":"2023-04-11"},"enrollment":269,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Melanoma","Recurrent Melanoma"],"interventions":[{"type":"DRUG","name":"Dacarbazine","otherNames":[]},{"type":"DRUG","name":"Fotemustine","otherNames":[]},{"type":"DRUG","name":"Interferon Alfa-2b","otherNames":[]}],"arms":[{"label":"A1","type":"EXPERIMENTAL"},{"label":"A2","type":"EXPERIMENTAL"},{"label":"B1","type":"ACTIVE_COMPARATOR"},{"label":"B2","type":"EXPERIMENTAL"}],"summary":"This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"24 months","effectByArm":[{"arm":"Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine","deltaMin":7.9,"sd":null},{"arm":"Dacarbazine/Interferon + Dacarbazine","deltaMin":8.6,"sd":null},{"arm":"Fotemustine/Dacarbazine/Interferon+Dacarbazine/Interferon","deltaMin":9.1,"sd":null},{"arm":"Fotemustine/Dacarbazine + Dacarbazine","deltaMin":7.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23402397"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":62},"commonTop":["Nausea/Vomiting","Diarrhoea"]}}